Key result
Monophasic subtype and metastasis at presentation are linked to worse overall survival in synovial sarcoma.
Why the study?
What are the independent prognostic factors for overall and progression-free survival in patients with synovial sarcoma?
Cohort (n=41)
What are the independent prognostic factors for overall and progression-free survival in patients with synovial sarcoma?
Histologic subtype (monophasic) is the single most important independent prognostic factor for synovial sarcoma regardless of tumor stage.
Answers are grounded in this paper and cite their sources.
Monophasic subtype and metastasis flag higher-risk synovial sarcoma; leaves open whether they should guide therapy intensity in prospective trials.
Many studies have described the diversity of synovial sarcoma in terms of its biological characteristics and clinical features. Moreover, much effort has been expended on the identification of prognostic factors because of unpredictable behaviors of synovial sarcomas. However, with the exception of tumor size, published results have been inconsistent. We attempted to identify independent risk factors using survival analysis. Forty-one consecutive patients with synovial sarcoma were prospectively followed from January 1997 to March 2008. Overall and progression-free survival for age, sex, tumor size, tumor location, metastasis at presentation, histologic subtype, chemotherapy, radiation therapy, and resection margin were analyzed, and standard multivariate Cox proportional hazard regression analysis was used to evaluate potential prognostic factors. Tumor size (>5 cm), nonlimb-based tumors, metastasis at presentation, and a monophasic subtype were associated with poorer overall survival. Multivariate analysis showed metastasis at presentation and monophasic tumor subtype affected overall survival. For the progression-free survival, monophasic subtype was found to be only 1 prognostic factor. The study confirmed that histologic subtype is the single most important independent prognostic factors of synovial sarcoma regardless of tumor stage.
No takes yet. Share an insight, caveat, or question.
Koh et al. (2009) conducted a cohort in Synovial sarcoma (n=41). Prognostic factors (including histologic subtype and metastasis) was evaluated on Overall survival and progression-free survival. Monophasic histologic subtype and metastasis at presentation were independent prognostic factors for poorer overall survival in patients with synovial sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: